In this free webinar, learn about parameters that limit the efficacy of current chimeric antigen receptor (CAR) T-cell therapies and enable the development of CAR T-cells with enhanced performance.

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys") and SpayVac for Wildlife, Inc. are pleased to ...

The paper, published in “Cancer Cell” on Nov. 7, describes a protein that prevents ... “I am confident to say that this ...

Catumaxomab was the first T-cell engager trifunctional antibody and the first drug in the world approved specifically for the treatment of MA and has since proven its safety and anti-tumor efficacy in ...

One-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast ...

A small trial used designer CAR T cells to reboot the immune systems of patients with three autoimmune diseases, but it's ...

T therapy targeting p95HER2 shows complete and durable tumor responses in HER2+ breast cancer preclinical models. Combining ...

Janux Therapeutics' innovative cancer treatment shows promise in reducing side effects and improving patient outcomes, but ...

ANKET ® ( A ntibody-based NK cell E ngager T herapeutics) is Innate's proprietary platform for developing next-generation, multi-specific natural killer (NK) cell engagers to treat certain types of ...

"We learned that the dysfunction in these T cells lies in their inability to kill tumors. Those genes were not being turned ...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T ...

One-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast ...